Educational attainment and diabetes risk: triangulation evidence from UK Biobank prospective cohort, NHANES 2011-2018, and cross-trait genomics analyses - Report - MDSpire
Advertisement
Educational attainment and diabetes risk: triangulation evidence from UK Biobank prospective cohort, NHANES 2011-2018, and cross-trait genomics analyses
Clinical Report: Association Between Educational Level and Diabetes Risk
Overview
This study investigates the relationship between educational attainment and diabetes risk, utilizing data from the UK Biobank and NHANES. Findings indicate that higher educational levels are associated with lower odds of prevalent and incident type 2 diabetes.
Background
Diabetes is a significant global health issue, contributing to morbidity and mortality. Educational attainment is recognized as a social determinant of health that influences health literacy, lifestyle behaviors, and access to healthcare.
Data Highlights
Study
Outcome
Odds Ratio (OR)
Hazard Ratio (HR)
UK Biobank
Prevalent T2D
0.76 (95% CI 0.72-0.79)
0.70 (95% CI 0.68-0.72)
NHANES
Prevalent T2D (College Graduation)
0.69 (95% CI 0.61-0.78)
N/A
Key Findings
Higher educational attainment is associated with lower odds of prevalent T2D (OR 0.76).
College/university degree holders have lower odds of prevalent T2D compared to those with no qualifications (OR 0.69).
In NHANES, college graduation or above correlates with lower prevalent T2D odds (OR 0.69).
Adiposity, smoking, alcohol use, and cardiometabolic biomarkers mediate the education-T2D association.
Genetically predicted educational attainment is inversely associated with BMI and T2D.
19 shared multi-SNP gene signals related to BMI/T2D were identified.
Clinical Implications
Healthcare professionals should consider educational attainment as a significant factor in diabetes risk assessment and management. Addressing educational disparities may help in developing targeted interventions for diabetes prevention.
Conclusion
The study indicates an association between higher educational attainment and reduced risk of type 2 diabetes.
In a 76-week randomized trial, patients with obesity without diabetes who received survodutide achieved greater weight loss and favorable changes in several metabolic measures compared with those who received placebo.
